These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 23084523)

  • 1. Targeting the androgen receptor.
    Friedlander TW; Ryan CJ
    Urol Clin North Am; 2012 Nov; 39(4):453-64. PubMed ID: 23084523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The evolving paradigm of second-line hormonal therapy options for castration-resistant prostate cancer.
    Courtney KD; Taplin ME
    Curr Opin Oncol; 2012 May; 24(3):272-7. PubMed ID: 22327837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC).
    Gupta E; Guthrie T; Tan W
    BMC Urol; 2014 Jul; 14():55. PubMed ID: 25062956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The androgen receptor, androgen synthesis, and new designer antiandrogens for metastatic castration-resistant prostate cancer: teaching old dogs new tricks.
    Lieberman R
    Am J Ther; 2013; 20(2):128-31. PubMed ID: 23466618
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
    Neuzillet Y; Flamand V; Lebdai S; Villers A; Lebret T
    Prog Urol; 2013 Oct; 23 Suppl 1():S34-43. PubMed ID: 24314737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
    Kim W; Ryan CJ
    Curr Treat Options Oncol; 2012 Jun; 13(2):189-200. PubMed ID: 22539224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Rehman Y; Rosenberg JE
    Drug Des Devel Ther; 2012; 6():13-8. PubMed ID: 22291466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.
    Porter LH; Bakshi A; Pook D; Clark A; Clouston D; Kourambas J; ; Goode DL; Risbridger GP; Taylor RA; Lawrence MG
    J Pathol; 2021 Jun; 254(2):121-134. PubMed ID: 33620092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model.
    Handratta VD; Vasaitis TS; Njar VC; Gediya LK; Kataria R; Chopra P; Newman D; Farquhar R; Guo Z; Qiu Y; Brodie AM
    J Med Chem; 2005 Apr; 48(8):2972-84. PubMed ID: 15828836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance emerges to second-generation antiandrogens in prostate cancer.
    Nelson WG; Yegnasubramanian S
    Cancer Discov; 2013 Sep; 3(9):971-4. PubMed ID: 24019330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New endocrine treatments prolong survival of patients with castration-resistant prostate cancer].
    Brasso K; Thomsen FB; Berg KD; Røder MA; Iversen P
    Ugeskr Laeger; 2013 Sep; 175(40):2328-32. PubMed ID: 24079321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
    Bambury RM; Rathkopf DE
    Urol Oncol; 2016 Aug; 34(8):348-55. PubMed ID: 26162486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.
    Shen HC; Balk SP
    Cancer Cell; 2009 Jun; 15(6):461-3. PubMed ID: 19477425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel antiandrogen, Compound 30, suppresses castration-resistant and MDV3100-resistant prostate cancer growth in vitro and in vivo.
    Kuruma H; Matsumoto H; Shiota M; Bishop J; Lamoureux F; Thomas C; Briere D; Los G; Gleave M; Fanjul A; Zoubeidi A
    Mol Cancer Ther; 2013 May; 12(5):567-76. PubMed ID: 23493310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer.
    Vasaitis T; Belosay A; Schayowitz A; Khandelwal A; Chopra P; Gediya LK; Guo Z; Fang HB; Njar VC; Brodie AM
    Mol Cancer Ther; 2008 Aug; 7(8):2348-57. PubMed ID: 18723482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ARN-509: a novel antiandrogen for prostate cancer treatment.
    Clegg NJ; Wongvipat J; Joseph JD; Tran C; Ouk S; Dilhas A; Chen Y; Grillot K; Bischoff ED; Cai L; Aparicio A; Dorow S; Arora V; Shao G; Qian J; Zhao H; Yang G; Cao C; Sensintaffar J; Wasielewska T; Herbert MR; Bonnefous C; Darimont B; Scher HI; Smith-Jones P; Klang M; Smith ND; De Stanchina E; Wu N; Ouerfelli O; Rix PJ; Heyman RA; Jung ME; Sawyers CL; Hager JH
    Cancer Res; 2012 Mar; 72(6):1494-503. PubMed ID: 22266222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the adrenal gland in castration-resistant prostate cancer: a case for orteronel, a selective CYP-17 17,20-lyase inhibitor.
    Zhu H; Garcia JA
    Curr Oncol Rep; 2013 Apr; 15(2):105-12. PubMed ID: 23371447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME; Antonarakis ES; Ferrante KJ; Horgan K; Blumenstein B; Saad F; Luo J; de Bono JS
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effect of the antiandrogen apalutamide (ARN-509) versus bicalutamide on the androgen receptor pathway in prostate cancer cell lines.
    Koukourakis MI; Kakouratos C; Kalamida D; Mitrakas A; Pouliliou S; Xanthopoulou E; Papadopoulou E; Fasoulaki V; Giatromanolaki A
    Anticancer Drugs; 2018 Apr; 29(4):323-333. PubMed ID: 29381490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the androgen receptor pathway in prostate cancer.
    Chen Y; Sawyers CL; Scher HI
    Curr Opin Pharmacol; 2008 Aug; 8(4):440-8. PubMed ID: 18674639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.